Back to search

Article

The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

2020-03-13

Abstract excerpt

<title>Abstract</title> <p>Background Intestinal microbiota restoration can be achieved by replacing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another application of interest is depletion of antibiotic resistant genes (ARGs) and organisms (AROs). In this study, we investigated fecal specimens from a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
56bb5ba7-c374-5199-9742-a182981b921e
DOI
10.21203/rs.3.rs-17152/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trialDOI 10.21203/rs.3.rs-17152/v1
Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trialSemantic proximity
Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trialSemantic proximity
Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD studySemantic proximity
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With RecurrentClostridioides difficileInfectionSemantic proximity
Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent RestorationSemantic proximity
Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection PreventionSemantic proximity
A rational approach for the targeted discovery and characterisation of microbiome-derived therapeuticsSemantic proximity
A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infectionSemantic proximity
Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent <i>Clostridium difficile</i> infectionSemantic proximity
Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent <i>Clostridium difficile</i> InfectionSemantic proximity
Prolonged effect of antibiotic therapy on the gut microbiota composition, functionality, and antibiotic resistance genes’ profiles in healthy stool donorsSemantic proximity
Identification of Simplified Microbial Communities That Inhibit Clostridioides difficile Infection through Dilution/ExtinctionSemantic proximity
Select a neighboring publication to make it the new centre.